Kinnate Biopharma Probability of Future Stock Price Finishing Under 4.84
| KNTEDelisted Stock | USD 2.96 0.27 8.36% |
Kinnate |
Kinnate Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Kinnate Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Kinnate Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Kinnate Biopharma is not yet fully synchronised with the market data | |
| Kinnate Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (112.65 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Kinnate Biopharma currently holds about 262.42 M in cash with (100.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 83.0% of the company shares are owned by institutional investors |
Kinnate Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Kinnate Stock often depends not only on the future outlook of the current and potential Kinnate Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Kinnate Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 46.6 M | |
| Cash And Short Term Investments | 154 M |
Kinnate Biopharma Technical Analysis
Kinnate Biopharma's future price can be derived by breaking down and analyzing its technical indicators over time. Kinnate Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Kinnate Biopharma. In general, you should focus on analyzing Kinnate Stock price patterns and their correlations with different microeconomic environments and drivers.
Kinnate Biopharma Predictive Forecast Models
Kinnate Biopharma's time-series forecasting models is one of many Kinnate Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Kinnate Biopharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Kinnate Biopharma
Checking the ongoing alerts about Kinnate Biopharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Kinnate Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Kinnate Biopharma is not yet fully synchronised with the market data | |
| Kinnate Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (112.65 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Kinnate Biopharma currently holds about 262.42 M in cash with (100.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 83.0% of the company shares are owned by institutional investors |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |